Clinical trial
Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of…
NCT00109161 · PDL BioPharma, Inc., Industry · Completed
Key facts
| NCT number | NCT00109161 |
|---|---|
| Title | Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis |
| Official title | A Phase II Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis |
| Lead sponsor | PDL BioPharma, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Daclizumab (Anti-CD25 Humanized Monoclonal Antibody) |
| Enrollment | 270 |
| Start date | Apr 1, 2005 |
| Completion | Oct 1, 2006 |
| First posted | Apr 25, 2005 |
| Last update posted | Aug 5, 2008 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: